Shanghai Haohai Biological Technology Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Shanghai Haohai Biological Technology heeft een totaal eigen vermogen van CN¥6.0B en een totale schuld van CN¥423.7M, wat de schuld-eigenvermogensverhouding op 7% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥7.2B en CN¥1.2B. De EBIT Shanghai Haohai Biological Technology is CN¥404.8M waardoor de rentedekking -6.4 is. Het heeft contanten en kortetermijnbeleggingen van CN¥2.7B.
Belangrijke informatie
7.0%
Verhouding schuld/eigen vermogen
CN¥423.70m
Schuld
| Rente dekkingsratio | -6.4x |
| Contant | CN¥2.69b |
| Aandelen | CN¥6.03b |
| Totaal verplichtingen | CN¥1.21b |
| Totaal activa | CN¥7.25b |
Recente financiële gezondheidsupdates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( CN¥3.7B ) 6826 } overtreffen de korte termijn passiva ( CN¥861.5M ).
Langlopende schulden: De kortetermijnactiva 6826 ( CN¥3.7B ) overtreffen de langetermijnschulden ( CN¥350.6M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 6826 heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van 6826 is de afgelopen 5 jaar gestegen van 0.7% naar 7%.
Schuldendekking: De schuld van 6826 wordt goed gedekt door de operationele kasstroom ( 159% ).
Rentedekking: 6826 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.